Drug Type Therapeutic vaccine, mRNA vaccine |
Synonyms CV 8102, CV8102 |
Target |
Mechanism RIG-I stimulants(Retinoic acid-inducible gene I stimulants), TLR7 agonists(Toll like receptor 7 agonists), TLR8 agonists(Toll like receptor 8 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Phase 2 | BE | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | BE | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | DE | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | DE | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | IT | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | IT | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | ES | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | ES | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | GB | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | GB | 18 Sep 2017 |
Phase 1 | 40 | bujrkaqbgf(klhrysargh) = eaajlmrebo ajcevmohbf (kwkvzyuumn ) | Positive | 11 Nov 2022 | |||
anti-PD-1 antibodies+CV8102 | bujrkaqbgf(klhrysargh) = nhcviumffm ajcevmohbf (kwkvzyuumn ) | ||||||
Phase 1/2 | 22 | hrxtxdprqk(izqremrpsq) = against ≥1 vaccinated HLA class I tumor-associated peptide (TAA) and ≥1 vaccinated HLA class II TAA were respectively induced in 37% and 53% of the vaccinees vofzoqornq (wpswwulnxa ) View more | Positive | 13 Jun 2022 | |||
Phase 1 | 58 | ffowctfduk(uxdpgeialv) = iqcmleknxm zeqtdwichz (zphbkwopin ) View more | Positive | 16 Sep 2021 | |||
anti-PD-1 antibodies+CV8102 | ffowctfduk(uxdpgeialv) = wgjinbizvy zeqtdwichz (zphbkwopin ) View more |